- Home
- XELB vs RDHL Comparison
XELB vs RDHL Comparison
Compare XELB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XELB
- RDHL
- Stock Information
- Founded
- XELB 2011
- RDHL 2009
- Country
- XELB United States
- RDHL Israel
- Employees
- XELB N/A
- RDHL N/A
- Industry
- XELB Multi-Sector Companies
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- XELB Miscellaneous
- RDHL Health Care
- Exchange
- XELB Nasdaq
- RDHL Nasdaq
- Market Cap
- XELB 4.6M
- RDHL 4.3M
- IPO Year
- XELB N/A
- RDHL N/A
- Fundamental
- Price
- XELB $1.66
- RDHL $2.15
- Analyst Decision
- XELB
- RDHL
- Analyst Count
- XELB 0
- RDHL 0
- Target Price
- XELB N/A
- RDHL N/A
- AVG Volume (30 Days)
- XELB 93.5K
- RDHL 18.4K
- Earning Date
- XELB 08-13-2025
- RDHL 08-28-2025
- Dividend Yield
- XELB N/A
- RDHL N/A
- EPS Growth
- XELB N/A
- RDHL N/A
- EPS
- XELB N/A
- RDHL N/A
- Revenue
- XELB $7,407,000.00
- RDHL $8,042,999.00
- Revenue This Year
- XELB $23.96
- RDHL $381.91
- Revenue Next Year
- XELB $53.02
- RDHL N/A
- P/E Ratio
- XELB N/A
- RDHL N/A
- Revenue Growth
- XELB N/A
- RDHL 23.17
- 52 Week Low
- XELB $1.51
- RDHL $1.71
- 52 Week High
- XELB $8.49
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- XELB 39.57
- RDHL 64.10
- Support Level
- XELB $1.51
- RDHL $2.00
- Resistance Level
- XELB $1.80
- RDHL $2.08
- Average True Range (ATR)
- XELB 0.16
- RDHL 0.09
- MACD
- XELB 0.01
- RDHL 0.03
- Stochastic Oscillator
- XELB 30.58
- RDHL 100.00
About XELB Xcel Brands Inc.
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.